484 related articles for article (PubMed ID: 19061836)
1. Distinct thresholds govern Myc's biological output in vivo.
Murphy DJ; Junttila MR; Pouyet L; Karnezis A; Shchors K; Bui DA; Brown-Swigart L; Johnson L; Evan GI
Cancer Cell; 2008 Dec; 14(6):447-57. PubMed ID: 19061836
[TBL] [Abstract][Full Text] [Related]
2. Developmental context determines latency of MYC-induced tumorigenesis.
Beer S; Zetterberg A; Ihrie RA; McTaggart RA; Yang Q; Bradon N; Arvanitis C; Attardi LD; Feng S; Ruebner B; Cardiff RD; Felsher DW
PLoS Biol; 2004 Nov; 2(11):e332. PubMed ID: 15455033
[TBL] [Abstract][Full Text] [Related]
3. The ARF tumor suppressor: keeping Myc on a leash.
Gregory MA; Qi Y; Hann SR
Cell Cycle; 2005 Feb; 4(2):249-52. PubMed ID: 15655352
[TBL] [Abstract][Full Text] [Related]
4. Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism.
Boone DN; Qi Y; Li Z; Hann SR
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):632-7. PubMed ID: 21187408
[TBL] [Abstract][Full Text] [Related]
5. p19ARF directly and differentially controls the functions of c-Myc independently of p53.
Qi Y; Gregory MA; Li Z; Brousal JP; West K; Hann SR
Nature; 2004 Oct; 431(7009):712-7. PubMed ID: 15361884
[TBL] [Abstract][Full Text] [Related]
6. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.
Pusapati RV; Rounbehler RJ; Hong S; Powers JT; Yan M; Kiguchi K; McArthur MJ; Wong PK; Johnson DG
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1446-51. PubMed ID: 16432227
[TBL] [Abstract][Full Text] [Related]
7. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL.
Maclean KH; Keller UB; Rodriguez-Galindo C; Nilsson JA; Cleveland JL
Mol Cell Biol; 2003 Oct; 23(20):7256-70. PubMed ID: 14517295
[TBL] [Abstract][Full Text] [Related]
8. Oncogenes and the DNA damage response: Myc and E2F1 engage the ATM signaling pathway to activate p53 and induce apoptosis.
Hong S; Pusapati RV; Powers JT; Johnson DG
Cell Cycle; 2006 Apr; 5(8):801-3. PubMed ID: 16582589
[TBL] [Abstract][Full Text] [Related]
9. MYC leads the way.
Venkateswaran N; Conacci-Sorrell M
Small GTPases; 2020 Mar; 11(2):86-94. PubMed ID: 29173017
[TBL] [Abstract][Full Text] [Related]
10. MYC, Metabolism, and Cancer.
Stine ZE; Walton ZE; Altman BJ; Hsieh AL; Dang CV
Cancer Discov; 2015 Oct; 5(10):1024-39. PubMed ID: 26382145
[TBL] [Abstract][Full Text] [Related]
11. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
Högstrand K; Grandien A
Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.
Valsesia-Wittmann S; Magdeleine M; Dupasquier S; Garin E; Jallas AC; Combaret V; Krause A; Leissner P; Puisieux A
Cancer Cell; 2004 Dec; 6(6):625-30. PubMed ID: 15607966
[TBL] [Abstract][Full Text] [Related]
13. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
15. The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.
Ota S; Zhou ZQ; Link JM; Hurlin PJ
Hum Mol Genet; 2009 Jul; 18(14):2609-21. PubMed ID: 19403560
[TBL] [Abstract][Full Text] [Related]
16. MYC and tumor metabolism: chicken and egg.
Dejure FR; Eilers M
EMBO J; 2017 Dec; 36(23):3409-3420. PubMed ID: 29127156
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis.
Bertwistle D; Sherr CJ
Blood; 2007 Jan; 109(2):792-4. PubMed ID: 16968893
[TBL] [Abstract][Full Text] [Related]
18. Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.
Hay J; Gilroy K; Huser C; Kilbey A; Mcdonald A; MacCallum A; Holroyd A; Cameron E; Neil JC
J Cell Biochem; 2019 Oct; 120(10):18332-18345. PubMed ID: 31257681
[TBL] [Abstract][Full Text] [Related]
19. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
[TBL] [Abstract][Full Text] [Related]
20. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
